This article first appeared on GuruFocus.
Release Date: October 17, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
-
Reliance Industries Ltd (WBO:RLI) reported strong…
Category: 6. Business
-
Reliance Industries Ltd (WBO:RLI) Q2 2026 Earnings Call Highlights: Strong Growth Across …
-
Rate of Second Primary Tumors Is Similar Between Adjuvant Cemiplimab and Placebo in High-Risk CSCC
Adjuvant treatment with cemiplimab-rwlc (Libtayo) was associated with a similar incidence of second primary tumors (SPTs) compared with placebo in patients with high-risk cutaneous squamous cell carcinoma (CSCC) following surgery and…
Continue Reading
-
Tarlatamab Improves Survival Vs Chemotherapy in Second-Line SCLC Subgroups
Treatment with tarlatamab-dlle (Imdelltra) improved overall survival (OS) vs chemotherapy among patients with small cell lung cancer (SCLC) regardless of chemotherapy-free intervals (CFIs) or prior receipt of anti–PD-(L)1 therapy, according to…
Continue Reading
-
ESMO 2025: Perioperative Enfortumab Vedotin (EV) plus Pembrolizumab (Pembro) in Participants with Muscle-Invasive Bladder Cancer (MIBC) Who Are Cisplatin-Ineligible: The Phase 3 KEYNOTE-905 Study – UroToday
- ESMO 2025: Perioperative Enfortumab Vedotin (EV) plus Pembrolizumab (Pembro) in Participants with Muscle-Invasive Bladder Cancer (MIBC) Who Are Cisplatin-Ineligible: The Phase 3 KEYNOTE-905 Study UroToday
- PADCEV™ Plus KEYTRUDA™, Given Before…
Continue Reading
-
Durvalumab Plus FLOT Ups Survival in Early Upper-GI Cancer – Medscape
- Durvalumab Plus FLOT Ups Survival in Early Upper-GI Cancer Medscape
- AstraZeneca, Inc. Announces Positive Results from the Matterorn Phase III Trial MarketScreener
- Imfinzi Plus Chemo Improves Survival in G/GEJ Adenocarcinoma CUREtoday.com
Continue Reading
-
Phase 2 BNT111/Cemiplimab Data Prove Positive in PD-(L)1-Relapsed/Refractory Melanoma
The addition of BNT111 to cemiplimab-rwlc (Libtayo) led to an objective response rate (ORR) of 18.1% (95% CI, 10.9%-27.4%; P = .0115) in patients with PD-(L)1-relapsed/refractory melanoma, allowing investigators to reject the null hypothesis of…
Continue Reading
-
T-DXd vs T-DM1 in HER2+ Early BC
DESTINY-Breast05 (NCT04622319), presented by Dr. Charles E. Geyer (Pittsburgh, United States of America) at the ESMO Congress 2025, is a pivotal phase 3, open-label, randomized trial evaluating trastuzumab deruxtecan (T-DXd)…
Continue Reading
-
ITM-11 Meets Primary and Secondary End Points in Final Trial Data in Patients with GEP-NETs | Targeted Oncology
Final analysis from the
phase 3 COMPETE trial (NCT03049189)1revealed that 177-Lu-edotretide (ITM-11) vs everolimus met its primary and secondary endpoints in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).The final…
Continue Reading
-
Indonesia and Israel eye increased trade relations
Indonesia and Israel eye increased trade relations | The Jerusalem PostJerusalem Post/Business & InnovationDue to the industrial crisis in Indonesia, the opportunity for cooperation with Israel is growing, especially in automation, robotics, AI…
Continue Reading
-
Regulator tells Horesh-Harel not to help choose ICC-CAL CEO
Regulator tells Horesh-Harel not to help choose ICC-CAL CEO | The Jerusalem PostJerusalem Post/Business & InnovationUnion Investments and Harel are due to buy the ICC-CAL stake at a company valuation of NIS 3.75-4 billion, depending on the credit…
Continue Reading